GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (STU:5RT) » Definitions » Gross-Profit-to-Asset %

Rubius Therapeutics (STU:5RT) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Rubius Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Rubius Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2022 was €0.00 Mil. Rubius Therapeutics's average Total Assets over the quarter that ended in Dec. 2022 was €97.09 Mil. Therefore, Rubius Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 0.00%.


Rubius Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Rubius Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rubius Therapeutics Gross-Profit-to-Asset % Chart

Rubius Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - - - -

Rubius Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rubius Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Rubius Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rubius Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rubius Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Rubius Therapeutics's Gross-Profit-to-Asset % falls into.



Rubius Therapeutics Gross-Profit-to-Asset % Calculation

Rubius Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (281.449+21.778)/ 2 )
=0/151.6135
=0.00 %

Rubius Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2022 )/( (Total Assets (Q: Sep. 2022 )+Total Assets (Q: Dec. 2022 ))/ count )
=0/( (172.404+21.778)/ 2 )
=0/97.091
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Rubius Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rubius Therapeutics (STU:5RT) Business Description

Traded in Other Exchanges
N/A
Address
124 Washington Street, Suite 101, Foxborough, MA, USA, 02035
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Rubius Therapeutics (STU:5RT) Headlines

No Headlines